Navigation Links
Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD

DANVERS, Mass., Aug. 7 /PRNewswire/ -- The results of a pilot study published in the Nutrition Journal ( suggest that children with attention deficit hyperactivity disorder (ADHD) can benefit from daily supplementation of high levels of purified fish oils. The eight-week study demonstrated that children who consumed between 8 and 16 grams per day of EPA and DHA (the long chain omega-3 fatty acids found in fish oil) showed significant improvements in their behavior rated by both their parents and the psychiatrist working with them.

The study monitored the ratio of two fatty acids in the blood: arachidonic acid (AA) and eicosapentaenoic acid (EPA). It has been known from previous studies that children with ADHD have a high AA/EPA ratio in the blood compared to control children. The amount of purified fish oil for each child was adjusted until his or her AA/EPA ratio reached ideal levels.

The study found a statistically significant improvement in inattention, hyperactivity, oppositional/defiant behavior and conduct disorders as the AA/EPA ratio in the blood was lowered. The findings were true for children taking their optimal dosage of drugs to manage their ADHD as well for the children who had voluntarily stopped taking their drugs during the study.

"This is an important study as it indicates when adequate levels of fish oil are added to the diet, significant behavioral changes can occur. This study also indicates that the growing epidemic of ADHD may have a strong nutritional component-the lack of sufficient intake of omega-3 fatty acids, such as EPA and DHA," said Dr. Barry Sears, one of the co-authors of the study. "Equally important is that supplementation with high-dose fish oil is synergistic with existing drugs, giving both the physician and parent new dietary approaches toward correcting this growing epidemic in our children."

About ADHD

ADHD is a neurological condition characterized by the inability to concentrate in a sustained manner, to pay attention to tasks, and to control impulsive actions. It is estimated that 3 to 7 percent of children have this disorder. For 60-80 percent of children with ADHD, the condition continues into adulthood.

About Dr. Sears

Dr. Barry Sears is one of the leading experts in the world in use of high- dose omega-3 fatty acids in the treatment of chronic disease conditions. He is the author of the New York Times #1 bestseller The Zone as well as 11 other books on his hormonal control technology, including The OmegaRx Zone and The Anti-Inflammation Zone. His books have sold more than 5 million copies in the United States and have been translated into 22 languages. He is the president of the Inflammation Research Foundation, a non-profit medical research organization that does clinical research in the areas of obesity, diabetes, heart disease, cancer, and neurological disorders.

SOURCE Zone Labs, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:11/30/2015)... Texas , Nov. 30, 2015  Hanger, Inc. ... amendment and restatement of the terms of its previously ... Solicitation") relating to its $200,000,000 aggregate principal amount 7⅛% ... other things, (i) the consent fees payable pursuant to ... on the Notes and (iii) the expiration date of ...
(Date:11/30/2015)... NAMUR , Belgium , Nov. 30, ... life sciences company focused on developing blood-based diagnostic tests for ... announced the Company will present at the LD Micro Conference, ... Los Angeles, CA. Attending from VolitionRx will ... and Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... While powdered supplements ... in wasted time. Fortunately, an inventor from Chesterfield, Va., has found an easy to ... keep the scoop used to measure powdered contents in a canister or other container ...
(Date:11/30/2015)... ... November 30, 2015 , ... Volpara Solutions ... density assessment and enterprise analytics solutions, here at the 101st Annual Radiological ... booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements of volumetric ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in the US ... is a long-term resorbable surgical mesh intended to support and reinforce soft tissue ...
(Date:11/30/2015)... ... November 30, 2015 , ... GKhair & Tibolli team members ... Juan Beauty Show held on November 8th and 9th at the Puerto Rico Convention ... hair artists, renowned beauticians and top of the line fashion journalists. The San Juan ...
Breaking Medicine News(10 mins):